New RCC Drug Combination Shows Improved Survival Outcomes
The FDA-approved treatment provides a new option for adults with advanced clear cell renal cell carcinoma.
Updated on Oct. 30, 2026 in Cancer
Live Poll
Should physicians prioritize long-term treatment sequencing when selecting a patient's first-line cancer therapy?
In September 2026, the FDA approved the combination of belzutifan and lenvatinib for adult patients with advanced renal cell carcinoma (RCC) that has a clear cell component. This therapy is intended for patients who have previously been treated with PD-1 or PD-L1 inhibitors.
Why it matters
This approval offers a new second-line treatment option for advanced RCC based on data showing improved progression-free survival compared to existing therapies. It provides an alternative for patients who have progressed after initial immunotherapy.
The FDA approval is based on the Phase 3 LITESPARK-011 trial, which demonstrated a median progression-free survival of 14.6 months for the combination versus 10.6 months for cabozantinib monotherapy, with a hazard ratio of 0.74 and a one-sided P-value of .00095.
The players
FDA
The federal agency responsible for regulating pharmaceuticals and public health in the United States.
The details
Belzutifan and lenvatinib work by targeting different pathways involved in tumor growth and blood vessel formation in clear cell renal cell carcinoma. The combination regimen aims to block these signals more effectively than standard monotherapy, which had previously been the standard for patients who had already failed PD-1 or PD-L1 inhibitor treatment.
Timeline
September 2026: The FDA approved the use of belzutifan plus lenvatinib for advanced renal cell carcinoma.
Health Landscape
This development shifts the second-line treatment landscape for advanced renal cell carcinoma by incorporating a dual-drug regimen into standard care. It represents a move away from relying primarily on tyrosine kinase inhibitor monotherapy after patients progress on PD-1 or PD-L1 inhibitors.
Patients with advanced clear cell RCC who have progressed on prior PD-1 or PD-L1 therapies may be eligible for this new regimen. It is worth discussing with your oncology team whether this combination is a suitable option for your specific treatment history and goals.
The takeaway
The combination of belzutifan and lenvatinib offers a clinically supported improvement in progression-free survival for advanced RCC patients. Patients and their physicians should track new treatment guidelines and discuss the potential benefits and side effects of this combination relative to individual patient needs.
Further reading
For more information on current treatment standards and ongoing developments, visit our Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Should physicians prioritize long-term treatment sequencing when selecting a patient's first-line cancer therapy?
